

Supplementary Figure 1. Intra-individual comparisons of antibody levels and neutralization capacity after 2 and 3 COVID-19 vaccine doses in older adults.

Matched intra-individual data post-dose 2 (PD2) and post-dose 3 (PD3) measurements of serum anti-Spike IgG (A), IgA (B) and IgM (C) antibodies, as well as anti-receptor binding domain (RBD) IgG (D), IgA (E), and IgM (F) antibodies. Matched intra-individual antibody neutralization capacity between 2 and 3 vaccine doses against wildtype (G) and beta variant (H) SARS-CoV-2. Dotted lines indicate the threshold of detection. Each data point indicates an individual participant and lines connect data from a single participant across post-dose 2 and post-dose 3 time points. Intra-individual associations between CMV serostatus and vaccine dose were assessed by paired two-way ANOVA, with Šidák's test post-hoc analysis. *$p<0.05$, **$p<0.01$, ***$p<0.001$.



Supplementary Figure 2. Antibodies by CMV serostatus and prior SARS-CoV-2 infection after two and three COVID-19 vaccines in older adults.

SARs-CoV-2 anti-Spike and anti-RBD antibodies were measured in serum by ELISA. Post-dose 2: anti-Spike IgG (A), IgA (B) and IgM (C) antibodies, and anti-receptor binding domain (RBD) IgG (D), IgA (E), and IgM (F) antibodies. Post-dose 3: anti-Spike IgG (G), IgA (H) and IgM (I) antibodies, and anti-receptor binding domain (RBD) IgG (J), IgA (K), and IgM (L) antibodies. Dotted lines indicate the threshold of detection. Each data point indicates an individual participant, and the center line indicates the median. Associations between CMV serostatus and prior COVID-19 were assessed by two-way ANOVA, with Tukey's test post-hoc analysis. *$p<0.05$, **$p<0.01$.



Supplementary Figure 3. Antibody neutralization capacity by CMV serostatus and prior SARS-CoV-2 infection after two and three COVID-19 vaccines in older adults. Serum antibody neutralization capacity was assessed by MNT50 with live SARS-CoV-2 virus. Post-dose 2: wildtype (A) and beta variant (B) SARS-CoV-2 neutralization. Post-dose 3: wildtype (C) and beta variant (D) SARS-CoV-2 neutralization. Dotted lines indicate the threshold of detection. Each data point indicates an individual participant, and the center line indicates the median. Associations between CMV serostatus and vaccine dose were assessed by two-way ANOVA, with Tukey's test post-hoc analysis.



Supplementary Figure 4. Effect of CMV serostatus on the circulating T cell repertoire in older adults.

T cell populations in whole blood were assessed by flow cytometry. (A) Prevalence of T cells as a proportion of total leukocytes. Prevalence of (B) $CD4^+$ T cells and (C) $CD8^+$ T cells as a proportion of total T cells. $CD4^+$ T cell subsets as a proportion of total $CD4^+$ T cells: (D) naïve; (E) central memory; (F) effector memory; (G) EMRA; (H) terminally differentiated. $CD8^+$ T cell subsets as a proportion of total $CD4^+$ T cells: (I) naïve; (J) central memory; (K) effector memory; (L) EMRA; (K) terminally differentiated. Each data point indicates an individual participant. Data are presented as box and whisker plots, minimum to maximum, where the center line indicates the median. Associations between T cell subsets and CMV serostatus were assessed by Student's *t* test with Welch's correction or Mann-Whitney *U* test, according to normality. **p<0.05, **p<0.01, ***p<0.001, ***p<0.0001.*



Supplementary Figure 5. Effects of CMV serostatus and prior COVID-19 on the circulating T cell repertoire in older adults – cell counts.

T cell populations in whole blood were assessed by flow cytometry. Absolute cell counts of: (A) total leukocytes; (B) total T cells; (C) total $CD4^+$ T cells. Absolute cell counts of $CD4^+$ T cells: (D) naïve; (E) central memory; (F) effector memory; (G) EMRA; (H) terminally differentiated. Absolute cell counts of $CD8^+$ T cells: (I) total; (J) naive; (K) central memory; (L) effector memory; (M) EMRA; (N) terminally differentiated. Each data point indicates an individual participant. Data are presented as box and whisker plots, minimum to maximum, where the center line indicates the median. Associations between CMV serostatus and prior COVID-19 were assessed by two-way ANOVA, with Tukey's test post-hoc analysis. ****p<0.001*, ****p<0.0001*.



Supplementary Figure 6. Effect of CMV serostatus and prior COVID-19 on the circulating T cell repertoire in older adults – frequency.

T cell populations in whole blood were assessed by flow cytometry. (A) Prevalence of $CD4^+$ T cells as a proportion of total T cells. $CD4^+$ T cell subsets as a proportion of total $CD4^+$ T cells: (B) naïve; (C) central memory; (D) effector memory; (E) EMRA; (F) terminally differentiated. $CD8^+$ T cell subsets as a proportion of total $CD8^+$ T cells: (G) naïve; (H) central memory; (I) effector memory; (J) EMRA; (K) terminally differentiated. Associations between T cell subsets and CMV serostatus were assessed by Student's t test with Welch's correction or Mann-Whitney U test, according to normality. Absolute cell counts of: (A) total leukocytes; (B) total T cells; (C) total $CD4^+$ T cells. Absolute cell counts of $CD4^+$ T cells: (D) naïve; (E) central memory; (F) effector memory; (G) EMRA; (H) terminally differentiated. Absolute cell counts of $CD8^+$ T cells: (I) total; (J) naive; (K) central memory; (L) effector memory; (M) EMRA; (N) terminally differentiated. Each data point indicates an individual participant. Data are presented as box and whisker plots, minimum to maximum, where the center line indicates the median. Associations between CMV serostatus and prior COVID-19 were assessed by two-way ANOVA, with Tukey's test post-hoc analysis. *$p<0.05$, **$p<0.01$, ***$p<0.001$, ***$p<0.0001$.



Supplementary Figure 7. Intra-individual comparisons of CD4$^+$ and CD8$^+$ T cell activation induced memory responses to SARS-CoV-2 Spike peptide pools in older adults by CMV serostatus.

T cell memory responses to SARS-CoV-2 Spike protein were assessed by activation induced marker assay. (A) Spike SARs-CoV-2-specific AIM$^+$CD8$^+$ T cells (expressing CD69 and CD137) as a proportion of total CD8$^+$ T cells. (B) Spike SARs-CoV-2-specific AIM$^+$CD4$^+$ T cells (expressing CD25 and OX40L) as a proportion of total CD4$^+$ T cells. Spike SARs-CoV-2-specific AIM$^+$CD4$^+$ T cell functional Th1 (C), Th2 (D), and Th17 (E) subsets. Each data point indicates an individual participant and lines connect data from a single participant across post-dose 2 and post-dose 3 time points. Intra-individual associations between CMV serostatus and vaccine dose were assessed by paired two-way ANOVA, with Šidák's test post-hoc analysis. **p<0.05, **p<0.01*.



Supplementary Figure 8. CD4$^+$ and CD8$^+$ T cell activation induced memory responses to SARS-CoV-2 Spike peptide pools after COVID-19 in older adults by CMV serostatus. Post-dose 2: (A) Spike SARs-CoV-2-specific AIM$^+$CD8$^+$ T cells (expressing CD69 and CD137) were measured as a proportion of total CD8$^+$ T cells. (B) Spike SARs-CoV-2-specific AIM+CD4+ T cells (expressing CD25 and OX40L) were measured as a proportion of total CD4+ T cells. Spike SARs-CoV-2-specific AIM$^+$CD4$^+$ T cell functional Th1 (C), Th2 (D), and Th17 (E) subsets. Post-dose 3: (F) Spike SARs-CoV-2-specific AIM$^+$CD8$^+$ T cells as a proportion of total CD8$^+$ T cells. (G) Spike SARs-CoV-2-specific AIM$^+$CD4$^+$ T cells as a proportion of total CD4$^+$ T cells. Spike SARs-CoV-2-specific AIM$^+$CD4$^+$ T cell functional Th1 (H), Th2 (I), and Th17 (J) subsets. Each data point indicates an individual participant. Data are presented as box and whisker plots, minimum to maximum, where the center line indicates the median. Associations between CMV serostatus and prior COVID-19 were assessed by two-way ANOVA, with Tukey's test post-hoc analysis. *$p<0.05$.



Supplementary Figure 9. CD4$^+$ and CD8$^+$ T cell activation induced memory responses to CytoStim and influenza HA peptide pools after COVID-19 in older adults by CMV serostatus. CytoStim-induced responses: (A) AIM$^+$CD8$^+$ T cells (expressing CD69 and CD137) as a proportion of total CD8$^+$ T cells; (B) AIM$^+$CD4$^+$ T cells (expressing CD25 and OX40L) as a proportion of total CD4$^+$ T cells; AIM$^+$CD4$^+$ T cell functional Th1 (C), Th2 (D), and Th17 (E) subsets. Influenza HA-induced responses: (F) AIM$^+$CD8$^+$ T cells (expressing CD69 and CD137) as a proportion of total CD8$^+$ T cells; (G) AIM$^+$CD4$^+$ T cells (expressing CD25 and OX40L) as a proportion of total CD4$^+$ T cells; AIM$^+$CD4$^+$ T cell functional Th1 (H), Th2 (I), and Th17 (J) subsets. Each data point indicates an individual participant. Data are presented as box and whisker plots, minimum to maximum, where the center line indicates the median. Associations between CMV serostatus and prior COVID-19 were assessed by two-way ANOVA, with Tukey's test post-hoc analysis. *$p<0.05$, **$p<0.01$, ***$p<0.001$.